Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07VIK
|
||||
| Former ID |
DAP001333
|
||||
| Drug Name |
Arsenic trioxide
|
||||
| Synonyms |
Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+); Oxygen(2-)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10:C91.0] | Approved | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
As2O3
|
||||
| Canonical SMILES |
[O-2].[O-2].[O-2].[As+3].[As+3]
|
||||
| InChI |
1S/2As.3O/q2*+3;3*-2
|
||||
| InChIKey |
QTLQKAJBUDWPIB-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 1327-53-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| ChEBI ID |
ChEBI:30621
|
||||
| SuperDrug ATC ID |
L01XX27
|
||||
| SuperDrug CAS ID |
cas=001327533
|
||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Malignant cancer cells | Target Info | Inhibitor | [3], [4] | |
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 078729. | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 3 | Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J. 2002 Jan-Feb;8(1):12-25. | ||||
| REF 4 | How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.